Abstract 662P
Background
IMM2520 consists of a PD-L1 antibody with an engineered ADCC-enhanced IgG1 Fc region, linked to the domain of SIRPα at the N-terminus of heavy chains. Blockade of PD-L1 and CD47- SIRPα pathway fully activate macrophages and induce enhanced ADCP and ADCC activity, leading to potent integrated antitumor response.
Methods
This is an open-label, first in human, dose escalation and dose expansion phase1 study to evaluate the safety, RP2D/MTD and anti-tumor effect for IMM2520 in pts with advanced solid tumor. The dose escalation was designed with an accelerated titration at first dose level followed by standard 3+3 design. IMM2520 was administered weekly in a 28 day-cycle. Additional patients will be enrolled for potential RP2D to identify optimized dose level. Here we report results in ongoing dose escalation stage.
Results
As of 4 Apr 2024, 18 patients (pts) were treated at 5 dose levels (from 0.1mpk to 4mpk). Most pts (61%) previously received ≥ 3 lines of systemic anti-tumor therapy, including 9 (50%) pts with PD-(L)1 therapy history. No DLTs were observed yet. All pts reported treatment-related adverse event (TRAE), of which 10 (56%) pts were ≥ Grade 3. The most common TRAE of any grade was platelet decreased (89%), anemia (67%), white blood cell decreased (56%) and infusion-related reaction (IRR) (56%). The most common TRAE of ≥ Grade 3 was lymphocyte decreased (50%), platelet decreased (33%) and anorexia (5.6%). No AE leading to treatment discontinuation was observed. Of 11 efficacy evaluable pts,1 unconfirmed partial response (PR) in small cell lung cancer (SCLC) at 2mpk (with 2 previous lines of therapy including immunotherapy and negative PD-L1 expression) and 5 stable disease (SD) were observed, including 1 cervical cancer with 21.1% tumor shrinkage and 1 colorectal cancer with 11.1% tumor shrinkage. Pharmacodynamic biomarker included CD47 Target occupancy (TO) on peripheral circulating CD3+T cells using flow cytometry analysis. The rate of CD47 TO was mild and exhibits a dose-dependent trend.
Conclusions
IMM2520 showed tolerance at the evaluated doses and preliminary anti-tumor activity in advanced solid tumor, especially for SCLC. The dose escalation is ongoing.
Clinical trial identification
NCT05780307.
Editorial acknowledgement
Legal entity responsible for the study
ImmuneOnco BioPharmaceuticals (Shanghai) Inc.
Funding
ImmuneOnco BioPharmaceuticals (Shanghai) Inc.
Disclosure
A. Wu, X. Zhao, Z. Wang, Q. Lu: Financial Interests, Personal, Full or part-time Employment: ImmuneOnco BioPharmaceuticals (Shanghai) Inc. W. Tian: Financial Interests, Personal, Stocks or ownership: ImmuneOnco BioPharmaceuticals (Shanghai) Inc. All other authors have declared no conflicts of interest.
Resources from the same session
621P - Phase II trial of encorafenib and binimetinib (E+B) in patients (pts) with BRAF-altered advanced solid tumors: Results of E+B cohort in the BELIEVE trial (NCCH1901)
Presenter: Yoshitaka Honma
Session: Poster session 01
622P - Safety and efficacy of ifebemtinib (IN10018) combined with D-1553 in solid tumors with KRAS G12C mutation: Results from a phase Ib/II study
Presenter: Zhengbo Song
Session: Poster session 01
624P - Belvarafenib in patients (pts) with BRAF class II or III alteration-positive tumours: TAPISTRY study
Presenter: Rafal Dziadziuszko
Session: Poster session 01
625P - Initial results from the phase I, first-in-human study of the covalent, PI3Kα inhibitor TOS-358 in patients with solid tumors, expressing PI3Kα mutations or amplifications
Presenter: Marwan Fakih
Session: Poster session 01
626P - Roginolisib (IOA-244), a first oral allosteric modulator of phosphoinositide 3-kinase inhibitor delta (PI3Kδ) in patients with metastatic uveal melanoma
Presenter: Anna Di Giacomo
Session: Poster session 01
627P - Long-term efficacy and safety of larotrectinib in non-primary central nervous system (CNS) TRK fusion cancer
Presenter: Alexander Drilon
Session: Poster session 01
628P - Efficacy and safety of larotrectinib as first-line treatment for patients (pts) with TRK fusion cancer: An updated analysis
Presenter: David Hong
Session: Poster session 01
629P - Phase I study of pamiparib and cabozantinib in patients with metastatic solid tumors harboring homologous recombination deficiency (HRD)
Presenter: Siqing Fu
Session: Poster session 01